| Metric | Details |
|---|---|
| Entity / Legal Name | Octapharma Plasma, Inc. (subsidiary of Octapharma AG) |
| Parent Company | Octapharma AG (Switzerland, privately held) |
| Credit Ratings | no verified rating |
| Investment Grade Status | Not Yet Verified |
| Sector | Healthcare / Plasma Collection & Biopharmaceutical |
| Headquarters | Charlotte, North Carolina (US operations) |
| Parent HQ | Lachen, Switzerland |
| Donation centers | Over 195 in the United States and Germany combined (Octapharma website, October 2026) |
| Parent annual revenue | €3.64 billion (Octapharma AG, 2025, company website) |
| Median asking cap rate | Insufficient tracked listings to report a median |
| Lease terms | Vary; confirm the lease type, term and rent increases in each lease |
| Guarantee Type | Varies; confirm the tenant entity (for example, Octapharma Plasma, Inc.) and any parent guaranty in each lease |
| Building Size | Varies; confirm for each center |
Octapharma Plasma: no confirmed agency rating. No rating for Octapharma Plasma has been verified against a primary source (an agency rating action or an issuer filing), so none is shown. If a rating is verified, it will appear here. Ratings checked October 8, 2026. See the investment grade credit tenant ratings table.
Octapharma Plasma Business Overview & NNN Investment Profile
Octapharma Plasma is the U.S. plasma collection subsidiary of Octapharma AG, a Swiss-based global biopharmaceutical company that makes human protein products derived from blood plasma. Octapharma AG reports €3.64 billion of revenue for 2025 and more than 11,000 employees on its website. Founded by Wolfgang Marguerre in 1983, it remains privately held and family owned, giving it four decades of experience in plasma-derived therapeutics. Octapharma reports over 195 plasma donation centers in the United States and Germany combined (October 2026), with its US collection network run by Octapharma Plasma, Inc. from Charlotte, North Carolina; other US plasma collectors include CSL Plasma, Grifols and BioLife Plasma Services.
For NNN investors, Octapharma Plasma centers represent a distinctive healthcare property type: purpose-built or extensively renovated facilities designed for high-volume plasma donation. Center size and location vary, so confirm them for each property; centers are built out for donor screening, plasma collection and storage. Source plasma is the raw material for therapies such as immunoglobulins, clotting factors and albumin, which are used to treat immune deficiencies, bleeding disorders and other serious medical conditions.
We did not locate a public credit rating for Octapharma AG from S&P, Moody’s or Fitch when we checked on October 8, 2026. Scale and a long operating history are positives, but without a public rating, its credit cannot be compared directly with rated peers such as Grifols, CSL and Takeda (the parent of BioLife), whose corporate or parent company ratings appear in the table below. Any view that Octapharma is equivalent to investment grade is an opinion, not a rating. Confirm the tenant entity in the lease and whether Octapharma AG provides a parent guaranty.
Why Octapharma Plasma Matters for NNN Investors
Plasma collection centers are a specialized healthcare property type. Plasma-derived therapies are made from donated human plasma, and Octapharma reports that over 80% of the plasma it uses comes from its own FDA-approved donation centers.
Octapharma Plasma lease types, terms, rent increases and tenant entities vary; confirm the term, increases and any parent guarantee in each lease. Specialized plasma-center fit-outs may increase conversion costs for a different use; assess each property. Other plasma collectors, such as CSL Plasma, BioLife or Grifols, could be prospects for a vacated center, but demand varies by market.
Cap Rates and Pricing for Octapharma Plasma NNN Properties
We do not currently track enough Octapharma Plasma listings with published asking cap rates to report a median. Pricing depends on the tenant entity and any guarantee, the remaining lease term, rent increases, the market and the cost of converting the space. Compare any offering with recent sales of plasma centers leased to Octapharma and to rated operators.
Credit ratings of selected plasma operators:
| Plasma collector | Entity | S&P / Moody’s |
|---|---|---|
| CSL Plasma | CSL Limited (parent) | A-/A3 |
| BioLife Plasma | Takeda (parent) | BBB+/Baa1 |
| Grifols | Grifols, S.A. | BB-/B1 |
| Octapharma Plasma | Octapharma AG (parent) | No public rating located (checked October 8, 2026) |
Ratings shown are corporate or parent company ratings, not guaranties of any property lease; confirm the tenant and any guarantor in each lease.
Frequently Asked Questions
Is Octapharma Plasma investment grade?
Not on an agency basis. We did not locate a public rating for Octapharma AG from S&P, Moody’s or Fitch (checked October 8, 2026), and any view that it is equivalent to investment grade is an opinion, not a rating. Confirm the tenant entity and any parent guaranty in the lease.
What asking cap rates do Octapharma Plasma NNN properties carry?
We do not currently track enough Octapharma Plasma listings to report a median asking cap rate. Pricing depends on the lease, the guarantee, the location and conversion cost; compare offerings with recent plasma center sales.
Octapharma Plasma Net Lease Property: Buying, Selling and Financing
Buying: We find on-market and off-market Octapharma Plasma properties, review the lease and the tenant’s credit, and compare pricing with current listings. On the majority of transactions, there is no separate fee to you as the buyer; the listing broker pays a cooperating commission.
Selling: We can prepare an opinion of value from current listings and recent sales and, when it fits your goals, run a confidential sale to private investors, family offices and institutional buyers. See our guide to off-market sales.
Financing: Investment Grade Capital, a service of Investment Grade LLC, matches buyers and owners with lenders for acquisitions and refinancing.
1031 exchanges: Tell us your identification and closing deadlines so we can plan the search around them.
Request an NNN investment consultation or email team@investmentgrade.com.
Related NNN Tenants
- Ascension
- Aspen Dental
- Athletico
- BioLife Plasma
- Concentra
- Corewell Health
- CSL Plasma
- DaVita Dialysis
- EyeCare Partners
- Fresenius
- Grifols
- Henry Ford Health
- HCA Healthcare
- Heartland Dental
- Mary Washington Healthcare
- McLaren Health Care
- Oak Street Health
- Piedmont Healthcare
- Sparrow Health
- Trinity Health
- U of M Health
- University of Pittsburgh Medical Center (UPMC)
- Acadia Healthcare
- AFC Urgent Care
- ATI Physical Therapy
- CityMD / Summit Health
- Encompass Health
- Fast Pace Urgent Care
- MedExpress Urgent Care
- MyEyeDr
- NextCare Urgent Care
- Pacific Dental Services
- Select Physical Therapy
- Smile Brands
- VCA Animal Hospitals
- WellNow Urgent Care
- Banfield Pet Hospital
- Labcorp
- National Vision
- Quest Diagnostics
Compare healthcare NNN credit before the 45-day deadline drives the decision
Healthcare net lease properties can look defensive, but the credit stack varies widely by tenant, guarantor, sponsor, reimbursement exposure, and real estate reusability. A 1031 buyer should compare the tenant’s credit support against cap rate, lease term, and alternate-use medical demand before treating the income stream as bond-like. In a 1031 exchange, replacement property generally must be identified within 45 days after the relinquished property is transferred (26 U.S.C. 1031(a)(3)); this is general information, not tax advice.
Use the 2026 NNN cap-rate framework and the investment-grade 1031 tenant shortlist to benchmark this healthcare tenant against stronger-credit replacement-property options.
